[Form 4] Vicarious Surgical Inc. Insider Trading Activity

Rhea-AI Filing Summary

Reporting person listed as FROM STEPHEN, identified as Chief Executive Officer and a director, was granted 297,600 stock options on 08/07/2025 with an $8.92 exercise price. The award vests 25% on August 7, 2026, with the remainder vesting in equal monthly installments over the following 36 months, subject to continued service. The options convert into Class A common stock, are reported as a direct holding, and show an apparent expiration date of 08/06/2035. The grant ties executive pay to share performance and creates potential dilution if the options are exercised.

Positive

• Material grant disclosed: The filing reports a clear award of 297,600 stock options to the CEO and director, providing transparency.
• Retention and alignment: Vesting schedule (25% at one year, then monthly over 36 months) ties executive incentives to long‑term share performance.

Negative

• Potential dilution: 297,600 options could dilute existing shareholders if exercised; the filing does not state outstanding share count or dilution percentage.
• Limited context: Filing does not provide board rationale, grant valuation beyond strike, or how this award compares to peer/previous grants.

Insights

Compensation Analyst

TL;DR: A large time‑based option award aligns CEO pay with stock performance but will dilute shares if exercised.

The grant of 297,600 options at an $8.92 strike is a sizable equity award by count and is structured with a one‑year cliff (25% vesting) followed by monthly vesting over three years, which is a common retention design. The ten‑year apparent term to 08/06/2035 provides a long exercise window. From a compensation perspective, the structure emphasizes retention and upside alignment; the report shows direct beneficial ownership, not indirect holdings.

Corporate Governance Expert

TL;DR: Routine executive equity grant disclosed; governance implications center on dilution, disclosure clarity, and alignment.

The Form 4 discloses a direct award to the CEO and director of 297,600 stock options with explicit vesting terms and an $8.92 exercise price. This is a standard equity compensation disclosure under Section 16. Key governance considerations are the size of the grant relative to outstanding equity (not provided here) and the explicit service‑based vesting schedule. The filing documents the mechanics but does not provide board approval rationale or relative grant metrics.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FROM STEPHEN

(Last) (First) (Middle)

C/O VICARIOUS SURGICAL INC.

78 FOURTH AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vicarious Surgical Inc. [ RBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.92	08/07/2025		A		297,600		(1)	08/06/2035	Class A Common Stock	297,600	$0.00	297,600	D

Explanation of Responses:

1. The shares underlying this option vest as to 25% of the award on August 7, 2026, with the remainder vesting in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each applicable vesting date.

	/s/ Erin Checka, Attorney-in-Fact	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Vicarious Surgical (RBOT)?

The reporting person is identified as FROM STEPHEN, listed as Chief Executive Officer and a director.

What security and amount were reported on the Form 4 for RBOT?

The Form 4 reports a grant of 297,600 stock options exercisable into Class A common stock.

What is the exercise price and grant date of the RBOT options?

The options carry an $8.92 exercise price and show a transaction (grant) date of 08/07/2025.

How do the RBOT options vest and when do they expire?

The options vest 25% on August 7, 2026, with the remainder vesting in equal monthly installments over the following 36 months; an apparent expiration date is 08/06/2035.

Is the reported ownership direct or indirect for RBOT?

The filing lists the ownership form as Direct (D) for the reported options.